Dermatologic TherapyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5

235 records returned

Original Article: Compounding dermatologic preparations in developing countriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Access to medications and their proper use are essential in developing countries. An interdisciplinary team of dermatologists and pharmacists created a master list of preparations useful for treating the most common dermatologic disorders in tropical and equatorial areas. The first pilot project was done at Cardinal Leger Hospital in Leogane, Haiti. Training was given to local staff at that hospital in 2005. Four years later, the clinic continues to prepare and offer, at a reasonable price, drugs that the population needs. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: Diane Lamarre, Marie-Ève Bertrand, Denis Giroux, James J. Nordlund, James Ertle, Alix J. Charles Tags: Original Articles Source Type: journals

Original Article: Superficial cutaneous fungal infections in tropical countriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Superficial fungal infections represent an important cause of morbidity for people worldwide, particularly in the tropics. Fungal infections affect the skin, hair, or the nails, and tend to thrive in the heat and humidity of tropical countries. Because of environmental and cultural factors unique to the tropics, the causative organisms and presentation of these infections may differ from those in industrialized countries. Treatment options include topical and systemic therapy. However, social and socioeconomic factors in developing tropical countries may necessitate different treatment approaches to achieve success. (Sourc...
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: Alix J. Charles Tags: Original Articles Source Type: journals

Imported tropical diseasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
are among the top three leading causes for morbidity and may affect up to 8% of returning travelers. Because the spectrum of dermatological manifestations seen in travelers is broad, it can be challenging for physicians to recognize and treat such conditions in a timely and efficient manner. Therefore, the present review highlights common imported tropical diseases with a focus on treatment regimens. Specifically, cutaneous larva migrans, myiasis, swimmer's itch, mycetoma, Chagas disease, and leishmaniasis are discussed. As awareness increases among travelers, immigrants, and health care providers regarding imported tropi...
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: Shaily Patel, Aisha Sethi Tags: Original Articles Source Type: journals

Treatment of leprosy/Hansen's disease in the early 21st centuryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Leprosy, or Hansen's disease (HD), is caused by Mycobacterium leprae, a slowly dividing mycobacterium that has evolved to be an intracellular parasite, causing skin lesions and nerve damage. Less than 5% of people exposed to M. leprae develop clinical disease. Host cell-mediated resistance determines whether an individual will develop paucibacillary or multibacillary disease. Hansen's disease is a worldwide disease with about 150 new cases reported annually in the United States. Effective anti-mycobacterial treatments are available, and many patients experience severe reversal and erythema nodosum leprosum reactions that a...
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: Sophie M. Worobec Tags: Original Articles Source Type: journals

Cutaneous ectoparasitesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Parasites inhabit many places in the world. Some of these can inhabit the human skin or body. Many of these have been eradicated in the developed countries but persist in some tropical environments that are fun places to visit. Visitors can bring such parasites home with them such as scabies, cutaneous larva migrans, tungiasis and myiasis. Their clinical manifestations and treatment are presented for physicians evaluating and treating travelers from exotic places. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: James J. Nordlund Tags: Original Articles Source Type: journals

Cutaneous and mucocutaneous leishmaniasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Leishmaniasis is a cluster of diseases caused by protozoa in the genus Leishmania. There are three basic clinical forms: cutaneous, mucocutaneous, and visceral leishmaniasis. The present review focuses on the diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Characteristics of both the human host and the parasite species influence the clinical disease manifestations that range from asymptomatic exposure, to self-healing skin ulcers, to life-threatening widespread destructive ulcerations. Whether through medical treatment or through spontaneous resolution, skin ulcerations generally result in disfiguring...
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: Consuelo V. David, Noah Craft Tags: Original Articles Source Type: journals

Filariasis: diagnosis and treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Filariasis is an infectious disease of the lymphatics and subcutaneous tissues caused by nematodes or filariae. Carried by mosquito vectors, this disease causes millions of people to suffer from lymphedema and elephantiasis, characteristics of filariasis infection. This disease can be diagnosed through the identification of microfilariae in blood or skin samples, antigen detection, radiographic imaging, or polymerase chain reaction. Mass drug administration by the World Health Organization has helped to diminish the incidence of filariasis. However, continued research on new drugs and vaccinations will be needed to control...
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: Natalia Mendoza, Alexa Li, Amber Gill, Stephen Tyring Tags: Original Articles Source Type: journals

Scabies and pyodermas – diagnosis and treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Scabies and pyodermas are two of the commonest skin infections in tropical settings. They affect large numbers of people, particularly children, and account for a large burden of disease for peripheral health care teams. Despite this there have been significant advances in our knowledge of these diseases, their impact and their management. However there is a need to evaluate these developments in this specific setting, tropical health and in the context of communities with limited resources. This section will describe these advances and the challenges that remain. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - November 4, 2009 Category: Dermatology Authors: R.J. Hay Tags: Original Articles Source Type: journals

Cutaneous leishmaniasis treated with itraconazoleEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case of cutaneous Leishmaniasis in a young girl successfully treated with itraconazole. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - November 3, 2009 Category: Dermatology Authors: A. Baroni, F. S. Aiello, A. Vozza, G. Vozza, F. Faccenda, M. Brasiello, E. Ruocco Tags: SIDeMaST Source Type: journals

An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Delayed pressure urticaria (DPU) is a physical urticaria characterized by the development of deep swellings at sites of pressure application on the skin. Etiopathogenesis of DPU is still unknown, although the available evidence suggests the involvement of mast cells through non-immunologic mechanisms and the role of several mediators beyond histamine, such as proinflammatory cytokines. The management of DPU is complex, also considering that prevention is very difficult and DPU frequently coexists with chronic "idiopathic" urticaria. Moreover, H1-antihistamines, which are the mainstay of treatment for common urticaria, usua...
Source: Dermatologic Therapy - November 3, 2009 Category: Dermatology Authors: Nicoletta Cassano, Valentina Mastrandrea, Michelangelo Vestita, Gino Antonio Vena Tags: SIDeMaST Source Type: journals

Ultrasound evaluation of clobetasol propionate 0.05% foam application in psoriatic and healthy skin: a pilot studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The aim of the present study was to evaluate through ultrasound imaging the response to treatment of twice and once daily application of clobetasol propionate 0.05% foam on psoriatic skin as well as the atrophogenic potential of once daily application of the foam on healthy skin. The study included a total of 40 participants, 30 affected by Psoriasis vulgaris and 10 healthy volunteers. Patients with psoriasis were branched in two groups of 15 subjects: in the first group, clobetasol propionate 0.05% foam was applied twice daily for up to 2 weeks on targeted plaques, in the second group, it was applied once daily for up to ...
Source: Dermatologic Therapy - November 3, 2009 Category: Dermatology Authors: Francesco Lacarrubba, Beatrice Nardone, Maria Letizia Musumeci, Giuseppe Micali Tags: SIDeMaST Source Type: journals

Treatment of erythrodermic psoriasis in HCV+ patient with adalimumabEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a high...
Source: Dermatologic Therapy - November 3, 2009 Category: Dermatology Authors: Antonio Giovanni Richetta, Elisa Maiani, Valentina Carlomagno, Valentina Carboni, Carlo Mattozzi, Simona Giancristoforo, Stefano Calvieri Tags: SIDeMaST Source Type: journals

Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repairEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Minimally ablative fractional laser devices have gained acceptance as a preferred method for skin resurfacing. Notable improvements in facial rhytides, photodamage, acne scarring, and skin laxity have been reported. The aim of the present work was to compare how different CO2 laser fluences, by modulating the secretory pathway of cytokines, are able to influence the wound-healing process, and how these fluences are associated with different clinical results. Eighteen patients, all with photodamaged skin, were treated using a fractional CO2 laser (SmartXide DOT, Deka M.E.L.A., Florence, Italy) with varying laser fluences (2...
Source: Dermatologic Therapy - November 3, 2009 Category: Dermatology Authors: F. Prignano, P. Campolmi, P. Bonan, F. Ricceri, G. Cannarozzo, M. Troiano, T. Lotti Tags: SIDeMaST Source Type: journals

Tropical dermatology and medicineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - November 1, 2009 Category: Dermatology Authors: James J. Nordlund, James Ertle Tags: Introduction Source Type: journals

Cutaneous lesions as initial signs of interferon α-induced sarcoidosis: report of three new cases and review of the literatureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report three new cases of mono-localized, purely cutaneous IFN[alpha]-induced sarcoidosis. In addition, an extensive review of the literature, with special attention to skin involvement, was performed through a PubMed search. The analysis of the retrieved articles showed that cutaneous lesions are frequent signs of IFN-induced sarcoidosis. Skin involvement is documented in 56% of the reports and it appears among the presenting and diagnostic signs of a sarcoid reaction in 51%. Special attention to dermatologic signs is imperative in the course of IFN therapy because even minimal skin involvement may offer a clue to an e...
Source: Dermatologic Therapy - November 1, 2009 Category: Dermatology Authors: Fabrizio Fantini, Claudia Padalino, Giulio Gualdi, Paola Monari, Alberto Giannetti Tags: SIDeMaST Source Type: journals

Can short courses of systemic corticosteroids truly cause osteonecrosis?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
One of the most feared complications of long-term corticosteroid therapy is osteonecrosis (avascular necrosis, aseptic necrosis). There is, no doubt, a causal role for systemic corticosteroids inducing osteonecrosis with such chronic therapy. The controversy involves whether short-term ( (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: Stephen E. Wolverton Tags: Original Articles Source Type: journals

Should dermatologists prescribe hormonal contraceptives for acne?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
One of the primary factors contributing to the development of acne vulgaris is excess sebum. Sebaceous glands and sebum excretion are regulated, at least in part, by androgen hormones. Acne treatments that block this androgen effect include spironolactone and combination oral contraceptives (COC). Three COC are now FDA approved to treat moderate acne. Dermatologists must become experts at prescribing these hormonal contraceptives. Likewise, it is vital to be aware of contraindications to hormonal contraceptive therapy. Proper patient selection relies on an appropriate medical history and an assessment of blood pressure. A ...
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: Julie C. Harper Tags: Original Articles Source Type: journals

Clinical risk management of Stevens–Johnson syndrome/toxic epidermal necrolysis spectrumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Clinical risk management concedes that risk is inherent to all health-care processes. Stevens[ndash]Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially life-threatening reactions to medications. Risk management should be considered prior to starting, during, and after therapy. Prior to starting therapy, risks that need to be assessed include any specific patient groups that may be at greater risk for the development of SJS/TEN. Gene testing is in place for Chinese and Thai patients who are going to be exposed to carbamazepine. During therapy, it is important to recognize SJS/TEN as a possib...
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: Sandra Knowles, Neil H. Shear Tags: Original Articles Source Type: journals

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We wil...
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: Eihab A. Alwawi, Eliana Krulig, Kenneth B. Gordon Tags: Original Articles Source Type: journals

Is there truly a risk of lymphoma from biologic therapies?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. Biologics are generally safe and well tolerated. However, there has been concern over the risk of lymphoma with use of these agents because of their immunosuppressive properties. This review summarizes the current evidence in regards to lymphoma risk with biologic therapy obtained from case reports and case series, observational studies, clinical trials, and meta-analyses. The majority of data for T-cell inhibitors comes from case reports and relatively small,...
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: Erica Dommasch, Joel M. Gelfand Tags: Original Articles Source Type: journals

Controversies in the management of the cutaneous T cell lymphomasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The primary cutaneous T cell lymphomas (CTCL) encompass all malignancies of the T cell where the skin is the primary organ of involvement. The diagnosis of a CTCL variant can be detoured by a number of obstacles including the slow evolution of the disease into a classic clinical and pathologic pattern. A realistic goal of early stage treatment is to reduce the likelihood of progression to a more advanced stage, not to achieve a cure. No studies have adequately compared the different systemic agents in patients with advanced CTCL so the clinician is left to act in the best interest of the patient with what evidence is avail...
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: John A. Zic Tags: Original Articles Source Type: journals

Topical antibiotics: therapeutic value or ecologic mischief?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Based on antibiotic prescribing data from 2003, dermatologists account annually for 8[ndash]9 million prescriptions for oral antibiotics, and 3[ndash]4 million prescriptions for topical antibiotics. Overall, much of the emphasis on concerns related to emergence of clinically significant antibiotic-resistant bacterial strains focuses on use of systemic antibiotics, however, topical antibiotic use may also have potential implications. The following article discusses the perspectives of the authors related to the potential therapeutic benefits and ecologic implications ("ecologic mischief") of topical antibiotic therapy for s...
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: James Q. Del Rosso, Grace K. Kim Tags: Original Articles Source Type: journals

Controversies in Dermatologic Drug TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - August 31, 2009 Category: Dermatology Authors: Stephen E. Wolverton Tags: Introduction Source Type: journals

ErratumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Vitiligo is an acquired depigmentation disorder affecting 1[ndash]4% of the world's population. Conventional therapies include steroids, photosensitive topical agents, surgical treatments, and phototherapy. The aim of the study was to evaluate the efficacy of monochromatic excimer light 308 nm (MEL), both as a monotherapy and in combination with khellin 4% ointment in vitiligo. Forty-height patients (36 male and 12 female) affected with vitiligo were enrolled in this open prospective study. Patients were selected and divided into three groups: group I included 16 patients treated with MEL 308 nm once-weekly and oral vitami...
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Rosita Saraceno, Steven P. Nisticò, Elisabetta Capriotti, Sergio Chimenti Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case of a patient affected by severe psoriasis and HCV infection. He underwent a first treatment with etenarcept with good clinical results and no change of his viral load. When etenarcept became ineffective, he received efalizumab, with a good control of his dermatological condition and a reduction of the viral load. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: F. Prignano, F. Zanieri, S. Milani, T. Lotti Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Focused UV-B narrowband microphototherapy (Biopsorin®). A new treatment for plaque psoriasisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report here on a new focused phototherapy method releasing UV-B with a peak at 311 nm, which consists in the selective irradiation of single psoriatic patches with a new device equipped with a special optic fiber. The treatment is effective, safe and well tolerated. Psoriasis Area and Severity Index 75 is achieved in 64% of patients after 12 sessions of treatment. The Physician Global Assessment evaluation significantly improves in all treated patients. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Torello Lotti, Lara Tripo, Marta Grazzini, Alena Krysenka, Gionata Buggiani, Vincenzo De Giorgi Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Angiomatous reaction Kaposi-sarcoma-like as a side effect of topical corticosteroid therapy in lichen sclerosus of the penisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the case of a 74-year-old man presented with a 6-month history of nodular lesions localized on penis. The man had a previous history of genital lesions that had been diagnosed as LS and treated with long-term topical corticosteroid therapy. After 3 months of corticosteroid therapy, the patient observed the appearance of several nodular erythematous lesions on the penis with progressive disappearance of the clinical symptoms of LS. These purple to red asymptomatic angiomatoid nodules resembled the clinical features of Kaposi sarcoma. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Caterina Catricalà, Samantha Marenda, Luca Maria Muscardin, Pietro Donati, Andrea Lepri, Laura Eibenschutz Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Zoonoses of dermatologic interestEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Zoonoses are infectious diseases that can be transmitted from animals to humans. Transmission occurs directly or through vectors such as ticks, mosquitoes, or flies. The causative agents include bacteria, parasites, viruses, and fungi. Domestic pets and livestock, as well as wild animals, can be the source of disease. In this summary, we will focus on a number of dermatologically relevant examples. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Morgan Wilson, Nektarios Lountzis, Tammie Ferringer Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Caterpillars and mothsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lepidoptera (moths, butterflies, and caterpillars) are an uncommon cause of adverse reactions in humans. Most reactions to Lepidoptera are mild and self-limited; however, reactions in sensitive individuals and reactions to particular species can be severe and life threatening. Specific syndromes caused by Lepidoptera include erucism (cutaneous reactions from contact with caterpillars, moths, or cocoons), lepidopterism (systemic involvement), ophthalmia nodosa (ocular involvement), dendrolimiasis and pararamose (each with joint symptoms relating to a specific species of caterpillar), lonomism (a severe hemorrhagic disease r...
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Eric W. Hossler Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

BedbugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cimex lectularius (the "bedbug") is an insect that feeds nocturnally, taking a requisite blood meal from a sleeping human or other parasitized host. Immunological reactions to bedbug saliva vary, but typically, bites yield erythematous and pruritic papules. The face and distal extremities, areas uncovered by sleeping clothes or blankets, are preferentially involved. Until the late 1990s, bedbug infestations in the United States were declining. Resurgence is attributed to increased travel and resistance to insecticides. Although hepatitis or human immunodeficiency virus is not effectively transmitted by the bedbug, pruritus...
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Adam Kolb, Glen R. Needham, Kimberly M. Neyman, Whitney A. High Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Mite infestationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article will review etiology, clinical manifestation, and treatment of mite infestations. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Damon McClain, Ali N. Dana, Gary Goldenberg Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Diagnosis and treatment of tick infestation and tick-borne diseases with cutaneous manifestationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article reviews the presentation of tick-borne illnesses and the medical management of these diseases. Among others, diseases such as ehrlichiosis, anaplasmosis, babesiosis, tularemia, borrelioses, tick-borne encephalitides, rickettsial spotted fevers, and tick typhus are discussed in this article. The recognition of skin manifestations associated with these diseases is paramount to early diagnosis and treatment initiation. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Ali N. Dana Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

ScabiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
is an ectoparasite caused by the mite Sarcoptes scabiei var hominis, an obligate human parasite. There are about 300 million cases of scabies in the world each year. Common predisposing factors are overcrowding, immigration, poor hygiene, poor nutritional status, homelessness, dementia, and sexual contact. Direct skin-to-skin contact between 15 and 20 minutes is needed to transfer the mites from one person to another. The diagnosis suspected with a clinical history of itch, worse at night, affecting other family members, clinical distribution, and appearance. Definite diagnosis relies on microscopic identification of the ...
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Maria I. Hicks, Dirk M. Elston Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Treatment of head liceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pediculosis capitis, or head lice, is a common infestation among children worldwide. Multiple therapies exist for the treatment of this condition, including topical pediculicides and oral medications. When used in combination with environmental decontamination, these drugs can be very effective in eradicating head lice infestation without significant adverse events. The present study discusses the use of available over-the-counter and prescription treatments, including pyrethroids and permethrin, lindane, malathion, ivermectin, and trimethoprim-sulfamethoxazole, in the treatment of head lice. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - July 1, 2009 Category: Dermatology Authors: Stephanie A. Diamantis, Dean S. Morrell, Craig N. Burkhart Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

Treatment of infestations, vector-borne, and zoonotic diseasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - June 30, 2009 Category: Dermatology Authors: Dirk Elston Tags: Treatment of Infestations, Vector-Borne and Zoonotic Diseases Source Type: journals

ErratumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Key opinion leaders: where they come from and how that affects the drugs you prescribeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Key opinion leaders (KOLs), also known as thought leaders, are the experts in their field upon whom we depend for original research leading to disease understanding and new therapies. We rely on them to write the articles, author the textbooks, and give the presentations that we absorb to become better dermatologists. KOLs have become intimately entwined with the marketing of pharmaceuticals and medical devices, used not only to lend credibility to claims of efficacy and safety but also to promote anecdotal and off-label use of these medications to increase industry profits. Identification and marketing of the KOLs themsel...
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Jeffrey J. Meffert Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Drug therapy in pediatrics: a developing fieldEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For many years, drug therapies were not explicitly studied in the pediatric population. The lack of data forced clinicians to treat children using empiric therapy, often guessing at the treatment dose. In addition to the lack of dosing information, there was no evidence that a product would be safe and efficacious in this unique population. Because dermatologic conditions are common in children, this lack of information affected dermatologists. In 1998, a new legislation passed that encouraged drug development in pediatrics. Additional legislation followed that allowed the Food and Drug Administration the authority to requ...
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Lisa Mathis, William Rodriguez Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Sources of drug information: FDA-approved labeling and other official FDA sourcesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To protect the public health and facilitate the safe and effective use of prescription drugs, the Food and Drug Administration (FDA) disseminates information through drug labeling, communication of safety issues, and the archiving of scientific reviews. The content and format requirements for professional labeling were revised in 2006 to improve the accessibility and usability of the information. New or emerging safety information is communicated using the formats of public health advisories (PHAs), information for heath care professional sheets, and early communications about ongoing safety reviews. The FDA analyses of ap...
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Jill A. Lindstrom Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Medical device regulation: what a practicing dermatologist should knowEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article is written by staff currently employed at the Center for Devices and Radiological Health and should provide information useful to the practicing dermatologist. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Jiyoung M. Dang, David Krause, Richard P. Felten, Markham K. Luke Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Generic drugs – safe, effective, and affordableEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article discusses the history and evolution of the process for generic drug evaluation and approval in the United States, with emphasis on locally acting dermatologic products. The requirements for in vivo bioequivalence (BE) testing and the statistical criteria for BE are discussed, and an example of a topical antifungal dermatologic product is used to demonstrate the BE determination for locally acting drugs. Other factors in the dispensing of prescription medications that are not within the Food and Drug Administration regulatory authority are also mentioned. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: John R. Peters, Dena R. Hixon, Dale P. Conner, Barbara M. Davit, Debra M. Catterson, Cecelia M. Parise Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Considerations before choosing (extemporaneously) compounded productsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite a plethora of pre-packaged topical products produced by the pharmaceutical industry for treating skin diseases, the practice of extemporaneous compounding continues, albeit at a low level ( (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Lincoln Krochmal Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Drugs and other product choicesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dermatologists have at their disposal a wide range of products to recommend or prescribe to their patients, all of which are regulated in some way by the Food and Drug Administration (FDA). However, the degree to which FDA has confirmed the safety and efficacy of a dermatological product can vary widely. Most prescription and some over-the-counter drugs and medical devices are approved by the FDA based on scientific data. Most over-the-counter drugs are marketed in compliance with FDA regulations based on expert medical review. The FDA clears most medical devices based on their substantial equivalence to other legally mark...
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Paul M. Hyman, Ricardo Carvajal Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Marketed pharmaceuticals are evaluated for safety by the US Food and Drug Administration (FDA) throughout the life cycle of the products. The FDA uses data from controlled clinical trials, from postmarketing case reports reported to the FDA's Adverse Event Reporting System, from epidemiological studies, and from registries to evaluate the safety of approved products. For some products, including some products used in dermatologic medicine, risks become apparent during the postmarketing period that require additional measures beyond product labeling and routine pharmacovigilance. The FDA continues to seek additional tools t...
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Joyce Weaver, Lois La Grenade, Hyon Kwon, Mark Avigan Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Clinical trials and statistical analyses: what should dermatologists look for in a report?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Clinicians need to evaluate the quality of individual clinical studies and synthesize the information from multiple clinical studies to provide insights in selecting appropriate therapies for patients. Understanding the key statistical principles that underlie a clinical trial and how they may be implemented can help clinicians properly interpret the efficacy and safety findings of clinical trials. Several factors should be considered when evaluating clinical studies reported in the literature, as important differences might exist among reported studies, thereby impacting the reliability of their findings. Studies vary in ...
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Mohamed Alosh, Kathleen Fritsch, Mat Soukup, Jonathan Wilkin Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Evaluating the severity of dermatologic disordersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Assessment of a patient's disease severity is an essential component of formulating therapeutic strategies. However, disorders of the skin are often not amenable to strict classification criteria, and the dermatologist relies upon personal thresholds of severity when assessing the patient's overall condition. A number of grading systems have arisen, primarily from the need for standardized end points in clinical trials; in some circumstances, these severity assessments may assist the clinician in the evaluation and treatment of dermatologic disease. In this review, we will summarize the results of available severity scores...
Source: Dermatologic Therapy - May 6, 2009 Category: Dermatology Authors: Sarah J. Grekin, Charles N. Ellis Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Choosing dermatologic therapiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - May 1, 2009 Category: Dermatology Authors: Jonathan Wilkin Tags: Choosing Dermatologic Therapies & #x2013; A User's Guide for Clinicians Source Type: journals

Vaccines under study: non-HIV vaccinesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article focuses on vaccines that have yet to be approved for licensure. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - March 25, 2009 Category: Dermatology Authors: Kelly Conner, Alice Wuu, Victoria Maldonado, Brenda L. Bartlett, Stephen K. Tyring Tags: Vaccines in Dermatology Source Type: journals

HIV vaccines under studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article will review the various current HIV vaccine candidates under study. (Source: Dermatologic Therapy)
Source: Dermatologic Therapy - March 25, 2009 Category: Dermatology Authors: Parisa Ravanfar, Natalia Mendoza, Anita Satyaprakash, Bilal I. Jordan Tags: Vaccines in Dermatology Source Type: journals